The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis

Documenti analoghi

• Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab
  di: Michael E. Wechsler, et al.
  Pubblicazione: (2025)
• Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis
  di: Michael E. Wechsler, et al.
  Pubblicazione: (2025)
• Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis With Polyangiitis: Findings From a Large European Cohort
  di: Matthias Papo, et al.
  Pubblicazione: (2026)
• Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis
  di: Alvise Berti, et al.
  Pubblicazione: (2026)
• A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis
  di: Carol A. Langford, et al.
  Pubblicazione: (2025)